Are biologics more effective than classical disease-modifying antirheumatic drugs?

Arthritis Research and Therapy

Volumn 10, Issue 5, 2008, Pages

  Nurmohamed, Michael T ^a,b   Dijkmans, Ben A C ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b JAN VAN BREEMEN INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ATLIZUMAB; BIOLOGICAL PRODUCT; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PREDNISOLONE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIRHEUMATIC AGENT;

CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; EVIDENCE BASED PRACTICE; HUMAN; LOW DRUG DOSE; MONOTHERAPY; NOTE; PATIENT IDENTIFICATION; RHEUMATOID ARTHRITIS; ARTICLE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; HUMANS;

EID: 60549088548     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2491     Document Type: Note

References (22)

1. Weinblatt ME Coblyn JS Fox DA Fraser PA Holdsworth DE Glass DN Trentham DE Efficacy of low-dose methotrexate in rheumatoid arthritis N Engl J Med 1985, 312:818-822. 3883172
2. O'Dell JR Treating rheumatoid arthritis early: A window of opportunity? Arthritis Rheum 2002, 46:283-285. 10.1002/art.10092 11840429
3. Smolen JS Aletaha D Keystone E Superior efficacy of combination therapy for rheumatoid arthritis: Fact or fiction? Arthritis Rheum 2005, 52:2975-2983. 10.1002/art.21293 16200577
4. Möttönen T Hannonen P Leirisalo-Repo M Nissilä M Kautiainen H Korpela M Laasonen L Julkunen H Luukkainen R Vuori K Paimela L Blåfield H Hakala M Ilva K Yli-Kerttula U Puolakka K Järvinen P Hakola M Piirainen H Ahonen J Pälvimäki I Forsberg S Koota K Friman C Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial. FIN-RACo trial group Lancet 1999, 353:1568-1573. 10.1016/ S0140-6736(98)08513-4 10334255
5. Boers M Verhoeven AC Markusse HM Laar van de MA Westhovens R van Denderen JC van Zeben D Dijkmans BA Peeters AJ Jacobs P Brink van den HR Schouten HJ Heijde van der DM Boonen A Linden van der S Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis Lancet 1997, 350:309-318. 10.1016/S0140-6736(97)01300-7 9251634
6. Landewé RB Boers M Verhoeven AC Westhovens R Laar van de MA Markusse HM van Denderen JC Westedt ML Peeters AJ Dijkmans BA Jacobs P Boonen A Heijde van der DM Linden van der S COBRA combination therapy in patients with early rheumatoid arthritis: Long-term structural benefits of a brief intervention Arthritis Rheum 2002, 46:347-356. 10.1002/ art.10083 11840436
7. Furst DE Breedveld FC Kalden JR Smolen JS Burmester GR Bijlsma JW Dougados M Emery P Keystone EC Klareskog L Mease PJ Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005 Ann Rheum Dis 2005, 64(Suppl 4):iV2-iv14. 10.1136/ard.2005.044941 16239380
8. Smolen JS Aletaha D Koeller M Weisman MH Emery P New therapies for treatment of rheumatoid arthritis Lancet 2007, 370:1861-1874. 10.1016/ S0140-6736(07)60784-3 17570481
9. Donahue KE Gartlehner G Jonas DE Lux LJ Thieda P Jonas BL Hansen RA Morgan LC Lohr KN Systematic review: Comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis Ann Intern Med 2008, 148:124-134. 18025440
10. Bathon JM Martin RW Fleischmann RM Tesser JR Schiff MH Keystone EC Genovese MC Wasko MC Moreland LW Weaver AL Markenson J Finck BK A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis N Engl J Med 2000, 343:1586-1593. 10.1056/ NEJM200011303432201 11096165
11. Klareskog L Heijde van der D de Jager JP Gough A Kalden J Malaise M Martín Mola E Pavelka K Sany J Settas L Wajdula J Pedersen R Fatenejad S Sanda M TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial Lancet 2004, 363:675-681. 10.1016/ S0140-6736(04)15640-7 15001324
12. Breedveld FC Weisman MH Kavanaugh AF Cohen SB Pavelka K van Vollenhoven R Sharp J Perez JL Spencer-Green GT The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment Arthritis Rheum 2006, 54:26-37. 10.1002/art.21519 16385520
13. Alonso-Ruiz A Pijoan JI Ansuategui E Urkaregi A Calabozo M Quintana A Tumor necrosis factor alpha drugs in rheumatoid arthritis: Systematic review and metaanalysis of efficacy and safety BMC Musculoskelet Disord 2008, 17:52. 10.1186/1471-2474-9-52 18419803 2377247
14. Emery P Breedveld FC Hall S Durez P Chang DJ Robertson D Singh A Pedersen RD Koenig AS Freundlich B Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): A randomised, double-blind, parallel treatment trial Lancet 2008, 372:375-382. 10.1016/ S0140-6736(08)61000-4 18635256
15. Heijde van der D Landewé R van Vollenhoven R Fatenejad S Klareskog L Level of radiographic damage and radiographic progression are determinants of physical function: A longitudinal analysis of the TEMPO trial Ann Rheum Dis 2008, 67:1267-1270. 10.1136/ard.2007.081331 18203764
16. Goekoop-Ruiterman YP de Vries-Bouwstra JK Allaart CF van Zeben D Kerstens PJ Hazes JM Zwinderman AH Ronday HK Han KH Westedt ML Gerards AH van Groenendael JH Lems WF van Krugten MV Breedveld FC Dijkmans BA Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial Arthritis Rheum 2005, 52:3381-3390. 10.1002/art.21405 16258899
17. Goekoop-Ruiterman YP de Vries-Bouwstra JK Allaart CF van Zeben D Kerstens PJ Hazes JM Zwinderman AH Peeters AJ de Jonge-Bok JM Mallée C de Beus WM de Sonnaville PB Ewals JA Breedveld FC Dijkmans BA Comparison of treatment strategies in early rheumatoid arthritis: A randomized trial Ann Intern Med 2007, 146:406-415. 17371885
18. O'Dell JR The BeSt way to treat early rheumatoid arthritis? Ann Intern Med 2007, 146:459-460. 17371891
19. Nurmohamed MT Dijkmans BA Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis Drugs 2005, 65:661-694. 10.2165/ 00003495-200565050-00006 15748099
20. Grigor C Capell H Stirling A McMahon AD Lock P Vallance R Kincaid W Porter D Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A single-blind randomised controlled trial Lancet 2004, 364:263-269. 10.1016/S0140-6736(04)16676-2 15262104
21. Klarenbeek NB Güler-Yüksel M Kooij van der SM Heijde van der DMFM Huizinga TWJ Kerstens PJSM Peeters AJ Ronday HK Westedt ML Dijkmans BAC Allaart CF Clinical outcomes of four different treatment strategies in patients with recent-onset rheumatoid arthritis: 5-years results of the BeSt-study [abstract] Ann Rheum Dis 2008, 67(Suppl II):187.
22. Nederlands Trial Register http://www.trialregister.nl/trialreg/admin/ rctview.asp?TC=1213